10.1083/jcb.150.3.589
10.1083/jcb.150.3.589 · doi-reference
Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus
10.1097/wnr.0b013e3280148e8b · doi-reference
Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology
10.1093/brain/awn323 · doi-reference
10.1093/hmg/ddr210
10.1093/hmg/ddr210 · doi-reference
10.1016/j.nbd.2011.12.046
10.1016/j.nbd.2011.12.046 · doi-reference
10.1016/j.jchemneu.2011.01.005
10.1016/j.jchemneu.2011.01.005 · doi-reference
Parkinson's disease is associated with hippocampal atrophy
10.1002/mds.10444 · doi-reference
10.1261/rna.783108
10.1261/rna.783108 · doi-reference
Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease
10.1111/j.1600-0404.1998.tb01736.x · doi-reference
Circulating interleukin-10 and interleukin-12 in Parkinson's disease
10.1111/j.1600-0404.2008.01103.x · doi-reference
Calpain as a potential therapeutic target in Parkinson's disease
10.2174/187152708784936680 · doi-reference
Axon responses of embryonic stem cell-derived dopaminergic neurons to semaphorins 3A and 3C
10.1002/jnr.22268 · doi-reference
10.1523/jneurosci.0702-05.2006
10.1523/jneurosci.0702-05.2006 · doi-reference
10.1212/wnl.0b013e31824c4728
10.1212/wnl.0b013e31824c4728 · doi-reference
Glutamate receptors as therapeutic targets for Parkinson's disease
10.2174/187152709789824606 · doi-reference
Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation
10.1002/(sici)1098-1136(20000215)29:4<305::aid-glia2>3.0.co;2-v · doi-reference
10.1111/j.1460-9568.2004.03254.x
10.1111/j.1460-9568.2004.03254.x · doi-reference
10.1006/bbrc.2000.4253
10.1006/bbrc.2000.4253 · doi-reference
10.1016/j.semcdb.2011.08.005
10.1016/j.semcdb.2011.08.005 · doi-reference
10.1111/j.1471-4159.2011.07284.x
10.1111/j.1471-4159.2011.07284.x · doi-reference
Disease-specific, neurosphere-derived cells as models for brain disorders
10.1242/dmm.005447 · doi-reference
10.1080/02656730500041871
10.1080/02656730500041871 · doi-reference
10.1038/ng882
10.1038/ng882 · doi-reference
Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau
10.1186/1750-1326-1-7 · doi-reference
Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles
10.1016/j.neulet.2009.12.078 · doi-reference
10.1016/j.febslet.2006.04.064
10.1016/j.febslet.2006.04.064 · doi-reference
10.1002/ana.20819
10.1002/ana.20819 · doi-reference
Tau therapeutic strategies for the treatment of Alzheimer's disease
10.2174/156802606776743057 · doi-reference
10.1016/j.biocel.2010.07.016
10.1016/j.biocel.2010.07.016 · doi-reference
10.1093/hmg/ddl190
10.1093/hmg/ddl190 · doi-reference
Tau and Parkinson Disease
10.1001/jama.286.18.2324 · doi-reference
α-Synuclein in Parkinson's disease
10.1101/cshperspect.a009399 · doi-reference
10.1111/j.1749-6632.2000.tb06900.x
10.1111/j.1749-6632.2000.tb06900.x · doi-reference
10.1146/annurev-neuro-061010-113613
10.1146/annurev-neuro-061010-113613 · doi-reference
Synucleinopathies: clinical and pathological implications
10.1001/archneur.58.2.186 · doi-reference
Leptin as a neuroprotective agent
10.1016/j.bbrc.2008.01.063 · doi-reference
10.1007/s12035-008-8032-1
10.1007/s12035-008-8032-1 · doi-reference
From the Cover: Epidermal growth factor receptor is a preferred target for treating Amyloid-induced memory loss
10.1073/pnas.1208011109 · doi-reference
BMP and FGF regulate the development of EGF-responsive neural progenitor cells
10.1242/dev.127.22.4993 · doi-reference
10.1242/dev.125.17.3417
10.1242/dev.125.17.3417 · doi-reference
